143 related articles for article (PubMed ID: 23158174)
1. Differentiation of small bowel and pancreatic neuroendocrine tumors by gene-expression profiling.
Carr JC; Boese EA; Spanheimer PM; Dahdaleh FS; Martin M; Calva D; Schafer B; Thole DM; Braun T; O'Dorisio TM; O'Dorisio MS; Howe JR
Surgery; 2012 Dec; 152(6):998-1007. PubMed ID: 23158174
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of membrane proteins in primary and metastatic gastrointestinal neuroendocrine tumors.
Carr JC; Sherman SK; Wang D; Dahdaleh FS; Bellizzi AM; O'Dorisio MS; O'Dorisio TM; Howe JR
Ann Surg Oncol; 2013 Dec; 20 Suppl 3(0 3):S739-S746. PubMed ID: 24114056
[TBL] [Abstract][Full Text] [Related]
3. Gene expression accurately distinguishes liver metastases of small bowel and pancreas neuroendocrine tumors.
Sherman SK; Maxwell JE; Carr JC; Wang D; Bellizzi AM; Sue O'Dorisio M; O'Dorisio TM; Howe JR
Clin Exp Metastasis; 2014 Dec; 31(8):935-44. PubMed ID: 25241033
[TBL] [Abstract][Full Text] [Related]
4. The Pancreas as a Site of Metastasis or Second Primary in Patients with Small Bowel Neuroendocrine Tumors.
Scott AT; Pelletier D; Maxwell JE; Sherman SK; Keck KJ; Li G; Dillon JS; O'Dorisio TM; Bellizzi AM; Howe JR
Ann Surg Oncol; 2019 Aug; 26(8):2525-2532. PubMed ID: 31011904
[TBL] [Abstract][Full Text] [Related]
5. Changes in gene expression in small bowel neuroendocrine tumors associated with progression to metastases.
Keck KJ; Breheny P; Braun TA; Darbro B; Li G; Dillon JS; Bellizzi AM; O'Dorisio TM; Howe JR
Surgery; 2018 Jan; 163(1):232-239. PubMed ID: 29154080
[TBL] [Abstract][Full Text] [Related]
6. A practical method to determine the site of unknown primary in metastatic neuroendocrine tumors.
Maxwell JE; Sherman SK; Stashek KM; O'Dorisio TM; Bellizzi AM; Howe JR
Surgery; 2014 Dec; 156(6):1359-65; discussion 1365-6. PubMed ID: 25456909
[TBL] [Abstract][Full Text] [Related]
7. MicroRNAs associated with small bowel neuroendocrine tumours and their metastases.
Miller HC; Frampton AE; Malczewska A; Ottaviani S; Stronach EA; Flora R; Kaemmerer D; Schwach G; Pfragner R; Faiz O; Kos-Kudła B; Hanna GB; Stebbing J; Castellano L; Frilling A
Endocr Relat Cancer; 2016 Sep; 23(9):711-26. PubMed ID: 27353039
[TBL] [Abstract][Full Text] [Related]
8. Gastric inhibitory polypeptide receptor (GIPR) is a promising target for imaging and therapy in neuroendocrine tumors.
Sherman SK; Carr JC; Wang D; O'Dorisio MS; O'Dorisio TM; Howe JR
Surgery; 2013 Dec; 154(6):1206-13; discussion 1214. PubMed ID: 24238043
[TBL] [Abstract][Full Text] [Related]
9. Pancreastatin predicts survival in neuroendocrine tumors.
Sherman SK; Maxwell JE; O'Dorisio MS; O'Dorisio TM; Howe JR
Ann Surg Oncol; 2014 Sep; 21(9):2971-80. PubMed ID: 24752611
[TBL] [Abstract][Full Text] [Related]
10. GIPR expression in gastric and duodenal neuroendocrine tumors.
Sherman SK; Maxwell JE; Carr JC; Wang D; O'Dorisio MS; O'Dorisio TM; Howe JR
J Surg Res; 2014 Aug; 190(2):587-93. PubMed ID: 24565507
[TBL] [Abstract][Full Text] [Related]
11. EPB41L5 is Associated With the Metastatic Potential of Low-grade Pancreatic Neuroendocrine Tumors.
Saller J; Seydafkan S; Shahid M; Gadara M; Cives M; Eschrich SA; Boulware D; Strosberg JR; Aejaz N; Coppola D
Cancer Genomics Proteomics; 2019; 16(5):309-318. PubMed ID: 31467225
[TBL] [Abstract][Full Text] [Related]
12. Defining molecular classifications and targets in gastroenteropancreatic neuroendocrine tumors through DNA microarray analysis.
Duerr EM; Mizukami Y; Ng A; Xavier RJ; Kikuchi H; Deshpande V; Warshaw AL; Glickman J; Kulke MH; Chung DC
Endocr Relat Cancer; 2008 Mar; 15(1):243-56. PubMed ID: 18310291
[TBL] [Abstract][Full Text] [Related]
13. Differences between Well-Differentiated Neuroendocrine Tumors and Ductal Adenocarcinomas of the Pancreas Assessed by Multi-Omics Profiling.
Starzyńska T; Karczmarski J; Paziewska A; Kulecka M; Kuśnierz K; Żeber-Lubecka N; Ambrożkiewicz F; Mikula M; Kos-Kudła B; Ostrowski J
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32586046
[TBL] [Abstract][Full Text] [Related]
14. The value of preoperative imaging in small bowel neuroendocrine tumors.
Dahdaleh FS; Lorenzen A; Rajput M; Carr JC; Liao J; Menda Y; O'Dorisio TM; Howe JR
Ann Surg Oncol; 2013 Jun; 20(6):1912-7. PubMed ID: 23283442
[TBL] [Abstract][Full Text] [Related]
15. Loss of expression of DNA mismatch repair proteins is rare in pancreatic and small intestinal neuroendocrine tumors.
Arnason T; Sapp HL; Rayson D; Barnes PJ; Drewniak M; Nassar BA; Huang WY
Arch Pathol Lab Med; 2011 Dec; 135(12):1539-44. PubMed ID: 22129180
[TBL] [Abstract][Full Text] [Related]
16. Is Multifocality an Indicator of Aggressive Behavior in Small Bowel Neuroendocrine Tumors?
Choi AB; Maxwell JE; Keck KJ; Bellizzi AJ; Dillon JS; OʼDorisio TM; Howe JR
Pancreas; 2017 Oct; 46(9):1115-1120. PubMed ID: 28902780
[TBL] [Abstract][Full Text] [Related]
17. DNA methylation profiles distinguish different subtypes of gastroenteropancreatic neuroendocrine tumors.
How-Kit A; Dejeux E; Dousset B; Renault V; Baudry M; Terris B; Tost J
Epigenomics; 2015; 7(8):1245-58. PubMed ID: 26360914
[TBL] [Abstract][Full Text] [Related]
18. Expression profiling of small intestinal neuroendocrine tumors identified pathways and gene networks linked to tumorigenesis and metastasis.
Wang Q; Yu C
Biosci Rep; 2020 Jun; 40(6):. PubMed ID: 32496505
[TBL] [Abstract][Full Text] [Related]
19. High VEGF serum values are associated with locoregional spread of gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Cigrovski Berković M; Čačev T; Catela Ivković T; Marout J; Ulamec M; Zjačić-Rotkvić V; Kapitanović S
Mol Cell Endocrinol; 2016 Apr; 425():61-8. PubMed ID: 26805636
[TBL] [Abstract][Full Text] [Related]
20. CLEC3A, MMP7, and LCN2 as novel markers for predicting recurrence in resected G1 and G2 pancreatic neuroendocrine tumors.
Miki M; Oono T; Fujimori N; Takaoka T; Kawabe K; Miyasaka Y; Ohtsuka T; Saito D; Nakamura M; Ohkawa Y; Oda Y; Suyama M; Ito T; Ogawa Y
Cancer Med; 2019 Jul; 8(8):3748-3760. PubMed ID: 31129920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
